New Committee on Rheumatologic Care (CORC) Chair Chris Phillips, MD, talks about his past work with the ACR, his experience as a private practice rheumatologist and his plans to lead CORC in addressing practitioner pain points and supporting the business side of rheumatology practice.
Speakers discussed common payer practices and policies that rheumatologists must navigate to secure and maintain appropriate care for their patients, including pharmacy benefit managers and prior authorization.
This legislative season has seen key pharmacy benefit manager reforms but slow movement on other issues, such as copay accumulators and utilization management. The ACR is also monitoring emerging topics, such as biomarker testing and post-public health emergency telehealth reforms.
The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1 “It’s crazy that medications are…
Rheumatologists should be better compensated, in part, due to the revenue they bring to the hospital system from their procedures, argue D’Anna et al., who found that clinical academic rheumatologists bring significant downstream revenue to the healthcare system.
In late August, leaders of state and local rheumatology societies from across the nation connected with each other and with ACR president Ken Saag, MD, in a roundtable-style meeting. State and local rheumatology leaders shared local updates, successes and challenges and discussed ACR initiatives.
Healthcare law is ever changing, particularly with regard to price transparency. Key healthcare leaders and stakeholders have long argued for more stringent price transparency regulations in an effort to increase patient awareness regarding the cost of a hospital item or service prior to receiving the service. Such information is anticipated to enable patients to take…
On Nov. 3, the inaugural, virtual Global Rheumatology Summit brought together specialists from all over the world to share critical expertise on global health issues related to rheumatology.
The use of biosimilar treatments is increasing, according to surveys conducted in 2018 and 2020 of rheumatologists from eight countries. In the two-year period, Japan had the largest increase in biosimilar prescriptions, with only 6% of surveyed rheumatologists reporting they prefer prescribing originator biologic agents.
Presenters at the Access in Rheumatology meeting held in advance of the ACR’s State-of-the-Art Clinical Symposium took a deep dive into the access challenges faced by rheumatology patients and discussed possible solutions. Treatment At least until 2026, prescription drug spending will exceed the U.S. gross domestic product (GDP) and health spending, said rheumatologist Colin C….